8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 24, 2026·SEC
Material company update
Feb 24, 2026·SEC
Standard BioTools Inc.(LAB)Earnings, Financials & Key Ratios
LAB•NASDAQ
Price updated Jun 19, 2026
AboutStandard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Standard BioTools Inc. was incorporated in 1999 and is headquartered in South San Francisco, California.Show more
- Revenue$85M-51.1%
- EBITDA-$92M+42.2%
- Net Income-$75M+46.1%
- EPS (Diluted)-0.20+61.5%
- Gross Margin49.86%+3.2%
- EBITDA Margin-107.34%-18.2%
- Operating Margin-109.34%-8.8%
- Net Margin-87.77%-10.2%
- ROE-16.72%+80.5%
LAB Key Insights
Standard BioTools Inc. (LAB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.7x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 17 (bottom 17%)
- ✗Sales declining 9.2% over 5 years
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when LAB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LAB Price & Volume
Standard BioTools Inc. (LAB) stock price & volume — 10-year historical chart
Loading chart...
LAB Growth Metrics
Standard BioTools Inc. (LAB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-2.92%
5 Years-9.19%
3 Years-4.49%
TTM-57.62%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM158.91%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM157%
Return on Capital
10 Years-26.51%
5 Years-31.95%
3 Years-30.66%
Last Year-18.55%
LAB Recent Earnings
Standard BioTools Inc. (LAB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.02+0.0%
$0.02
Rev
$21M+18.8%
$18M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$0.06+300.0%
$0.03
Rev
$24M+28.6%
$19M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.04-60.0%
$0.03
Rev
$20M+5.7%
$19M
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.04+0.0%
$0.04
Rev
$22M-46.7%
$41M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.02vs $0.02+0.0% | $21Mvs $18M+18.8% |
| Q1 2026 | Feb 24, 2026 | $0.06vs $0.03+300.0% | $24Mvs $19M+28.6% |
| Q4 2025 | Nov 4, 2025 | $0.04vs $0.03-60.0% | $20Mvs $19M+5.7% |
| Q3 2025 | Aug 11, 2025 | $0.04vs $0.04+0.0% | $22Mvs $41M-46.7% |
Based on last 12 quarters of dataView full earnings history →
LAB Peer Comparison
Standard BioTools Inc. (LAB) competitors in Device suppliers, distribution, and services — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AZTA | 1.07B | 23.31 | -19.11 | 3.55% | -29.86% | -10.69% | 0.06 | |
 NTRA | 33.14B | 231.41 | -152.24 | 35.9% | -9.05% | -15.13% | 0.13 | |
 PACB | 434.84M | 1.40 | -0.77 | 3.89% | -80.34% | -488.45% | 141.98 | |
 SEER | 95.67M | 1.74 | -1.36 | 15.57% | -468.74% | -26.58% | 0.09 | |
 CDNA | 1.35B | 26.18 | -65.45 | 13.79% | -1.98% | -2.61% | 0.06 | |
 ILMN | 24.6B | 161.93 | 29.71 | -0.78% | 19.43% | 32.84% | 0.94 | |
 TMO | 172.66B | 464.61 | 26.19 | 3.91% | 15.18% | 13.23% | 0.76 | |
 DHR | 125.4B | 177.17 | 35.15 | 2.9% | 14.89% | 7.06% | 0.35 |
Compare LAB vs Peers
Standard BioTools Inc. (LAB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LAB Income Statement
Standard BioTools Inc. (LAB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 101.94M | 112.96M | 117.24M | 138.14M | 130.58M | 97.95M | 106.34M | 174.43M | 85.33M | 65.68M |
Revenue Growth % | -2.4% | 10.82% | 3.79% | 17.83% | -5.47% | -24.99% | 8.57% | 64.03% | -51.08% | -57.62% |
Cost of Goods Sold | 49.95M | 51.31M | 52.96M | 54.82M | 61.21M | 60.9M | 55.89M | 90.17M | 42.79M | 31.57M |
COGS % of Revenue | 49.01% | 45.43% | 45.17% | 39.68% | 46.87% | 62.17% | 52.56% | 51.69% | 50.14% | - |
Gross Profit | 51.98M▲ 0% | 61.65M▲ 18.6% | 64.28M▲ 4.3% | 83.33M▲ 29.6% | 69.37M▼ 16.7% | 37.05M▼ 46.6% | 50.45M▲ 36.2% | 84.26M▲ 67.0% | 42.54M▼ 49.5% | 34.11M▲ 0% |
Gross Margin % | 50.99% | 54.57% | 54.83% | 60.32% | 53.13% | 37.83% | 47.44% | 48.31% | 49.86% | 51.93% |
Gross Profit Growth % | -11.05% | 18.6% | 4.27% | 29.63% | -16.75% | -46.59% | 36.16% | 67.02% | -49.51% | - |
Operating Expenses | 110.34M | 109.81M | 116.12M | 134.36M | 136.83M | 153.26M | 127.05M | 259.5M | 135.85M | 103.86M |
OpEx % of Revenue | 108.25% | 97.21% | 99.04% | 97.26% | 104.79% | 156.47% | 119.48% | 148.77% | 159.2% | - |
Selling, General & Admin | 79.52M | 79.78M | 84.48M | 97.9M | 98.89M | 102.28M | 87.54M | 156.61M | 109.86M | 98.64M |
SG&A % of Revenue | 78% | 70.63% | 72.05% | 70.87% | 75.73% | 104.43% | 82.32% | 89.78% | 128.75% | - |
Research & Development | 30.83M | 30.03M | 31.64M | 36.46M | 37.94M | 37.38M | 25.95M | 62.41M | 25.99M | 22.66M |
R&D % of Revenue | 30.24% | 26.58% | 26.99% | 26.39% | 29.06% | 38.17% | 24.4% | 35.78% | 30.45% | - |
Other Operating Expenses | 385K | 637K | 0 | 0 | 0 | 13.59M | 13.56M | 40.48M | 0 | 0 |
Operating Income | -58.36M▲ 0% | -48.16M▲ 17.5% | -51.84M▼ 7.6% | -51.04M▲ 1.5% | -67.46M▼ 32.2% | -116.2M▼ 72.3% | -76.6M▲ 34.1% | -175.24M▼ 128.8% | -93.31M▲ 46.8% | -72.83M▲ 0% |
Operating Margin % | -57.25% | -42.64% | -44.21% | -36.94% | -51.66% | -118.64% | -72.03% | -100.46% | -109.34% | -110.88% |
Operating Income Growth % | 20.26% | 17.47% | -7.63% | 1.55% | -32.18% | -72.26% | 34.08% | -128.77% | 46.75% | - |
EBITDA | -40.06M | -31.66M | -36.03M | -35.11M | -51.89M | -101.18M | -61.42M | -158.38M | -91.59M | -65.95M |
EBITDA Margin % | -39.3% | -28.03% | -30.73% | -25.42% | -39.74% | -103.3% | -57.76% | -90.79% | -107.34% | -100.41% |
EBITDA Growth % | 27.5% | 20.96% | -13.8% | 2.56% | -47.78% | -94.99% | 39.3% | -157.86% | 42.17% | 41.08% |
D&A (Non-Cash Add-back) | 18.3M | 16.5M | 15.8M | 15.92M | 15.57M | 15.03M | 15.18M | 16.86M | 1.72M | 6.88M |
EBIT | -57.98M | -47.53M | -62.43M | -50.53M | -59.84M | -188.6M | -69.64M | -135M | -96.68M | -70.49M |
Net Interest Income | -5.82M | -13.89M | -4.28M | -3.57M | -3.82M | -2.1M | 1M | 16.88M | 9.15M | 6.24M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 2.23M | 5.57M | 20.2M | 9.18M | 6.26M |
Interest Expense | 5.82M | 13.89M | 4.28M | 3.57M | 3.82M | 4.33M | 4.57M | 3.32M | 26K | 24K |
Other Income/Expense | -5.44M | -13.26M | -14.87M | -3.06M | 3.8M | -76.72M | 2.4M | 36.92M | -3.4M | -12.3M |
Pretax Income | -63.8M▲ 0% | -61.42M▲ 3.7% | -66.7M▼ 8.6% | -54.1M▲ 18.9% | -63.66M▼ 17.7% | -192.93M▼ 203.1% | -74.2M▲ 61.5% | -138.31M▼ 86.4% | -96.7M▲ 30.1% | -85.13M▲ 0% |
Pretax Margin % | -62.59% | -54.37% | -56.89% | -39.16% | -48.75% | -196.97% | -69.78% | -79.29% | -113.33% | -129.61% |
Income Tax | -3.26M | -2.41M | -1.92M | -1.08M | -4.42M | -2.83M | 452K | 573K | -37.88M | -37.74M |
Effective Tax Rate % | 5.12% | 3.92% | 2.87% | 2% | 6.95% | 1.47% | -0.61% | -0.41% | 39.17% | 44.33% |
Net Income | -60.53M▲ 0% | -59.01M▲ 2.5% | -64.79M▼ 9.8% | -53.02M▲ 18.2% | -59.24M▼ 11.7% | -190.1M▼ 220.9% | -74.66M▲ 60.7% | -138.88M▼ 86.0% | -74.9M▲ 46.1% | 78.2M▲ 0% |
Net Margin % | -59.38% | -52.24% | -55.26% | -38.38% | -45.36% | -194.08% | -70.2% | -79.62% | -87.77% | 119.07% |
Net Income Growth % | 20.33% | 2.51% | -9.79% | 18.17% | -11.73% | -220.91% | 60.73% | -86.03% | 46.07% | 158.91% |
Net Income (Continuing) | -60.53M | -59.01M | -64.79M | -53.02M | -59.24M | -190.1M | -74.66M | -138.88M | -58.83M | 91.61M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -16.07M | -1000K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.84▲ 0% | -1.49▲ 19.0% | -0.97▲ 34.9% | -0.74▲ 23.7% | -0.78▼ 5.4% | -2.43▼ 211.5% | -0.94▲ 61.3% | -0.52▲ 44.7% | -0.20▲ 61.5% | 0.20▲ 0% |
EPS Growth % | 29.77% | 19.02% | 34.9% | 23.71% | -5.41% | -211.54% | 61.32% | 44.68% | 61.54% | 157% |
EPS (Basic) | -1.84 | -1.49 | -0.97 | -0.74 | -0.78 | -2.43 | -0.94 | -0.52 | -0.20 | - |
Diluted Shares Outstanding | 32.98M | 39.65M | 66.78M | 72.04M | 75.79M | 78.31M | 79.16M | 352.67M | 381.62M | 388.2M |
Basic Shares Outstanding | 32.98M | 39.65M | 66.78M | 72.04M | 75.79M | 78.31M | 79.16M | 352.67M | 381.62M | 388.2M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
LAB Balance Sheet
Standard BioTools Inc. (LAB) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 94.8M | 127.11M | 96.1M | 117.66M | 72.07M | 208.81M | 158.22M | 375.88M | 454.26M | 521.45M |
Cash & Short-Term Investments | 63.14M | 95.4M | 58.64M | 68.52M | 28.45M | 165.78M | 114.89M | 292.87M | 187.57M | 455.18M |
Cash Only | 58.06M | 95.4M | 21.66M | 68.52M | 28.45M | 81.31M | 51.7M | 166.73M | 118.21M | 265.77M |
Short-Term Investments | 5.08M | 0 | 36.98M | 0 | 0 | 84.47M | 63.19M | 126.15M | 69.36M | 189.4M |
Accounts Receivable | 15.05M | 16.65M | 18.98M | 25.42M | 18.32M | 17.28M | 19.66M | 33.61M | 13.43M | 16.64M |
Days Sales Outstanding | 53.89 | 53.8 | 59.09 | 67.17 | 51.21 | 64.39 | 67.48 | 70.32 | 57.45 | 80.88 |
Inventory | 15.09M | 13M | 13.88M | 19.69M | 20.82M | 21.47M | 20.53M | 40.74M | 19.98M | 18.59M |
Days Inventory Outstanding | 110.24 | 92.49 | 95.68 | 131.1 | 124.19 | 128.7 | 134.09 | 164.9 | 170.45 | 254.81 |
Other Current Assets | 1.53M | 2.05M | 0 | 0 | 16K | 4.28M | 3.13M | 8.66M | 233.28M | 31.05M |
Total Non-Current Assets | 192.55M | 176.54M | 168.72M | 207.09M | 203.15M | 181.5M | 164.85M | 236.46M | 113.49M | 117.66M |
Property, Plant & Equipment | 12.3M | 8.82M | 12.92M | 55.65M | 65.15M | 59.53M | 54.85M | 71.38M | 46.01M | 42.65M |
Fixed Asset Turnover | 8.29x | 12.80x | 9.08x | 2.48x | 2.00x | 1.65x | 1.94x | 2.44x | 1.85x | 1.46x |
Goodwill | 104.11M | 104.11M | 104.11M | 106.56M | 106.38M | 106.25M | 106.32M | 111.3M | 0 | 0 |
Intangible Assets | 68.6M | 57.4M | 49.13M | 42.22M | 27.93M | 12.6M | 1.4M | 28.95M | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 1M | 0 | 0 | 0 | 25.7M | 116.54M |
Other Non-Current Assets | 7.54M | 6.21M | 2.56M | 2.66M | 3.69M | 3.11M | 2.29M | 24.83M | 3.15M | 3.39M |
Total Assets | 287.35M▲ 0% | 303.65M▲ 5.7% | 264.81M▼ 12.8% | 324.76M▲ 22.6% | 275.21M▼ 15.3% | 390.31M▲ 41.8% | 323.07M▼ 17.2% | 612.34M▲ 89.5% | 567.75M▼ 7.3% | 639.11M▲ 0% |
Asset Turnover | 0.35x | 0.37x | 0.44x | 0.43x | 0.47x | 0.25x | 0.33x | 0.28x | 0.15x | 0.11x |
Asset Growth % | -6.22% | 5.67% | -12.79% | 22.64% | -15.26% | 41.82% | -17.23% | 89.54% | -7.28% | -39.25% |
Total Current Liabilities | 33.47M | 37.58M | 32.82M | 54.25M | 49.57M | 43.44M | 109.33M | 65.89M | 108.31M | 42.2M |
Accounts Payable | 4.21M | 4.03M | 5.15M | 9.22M | 10.6M | 7.91M | 9.24M | 12.28M | 5.41M | 8.01M |
Days Payables Outstanding | 30.77 | 28.64 | 35.5 | 61.39 | 63.22 | 47.43 | 60.32 | 49.72 | 46.12 | 79.08 |
Short-Term Debt | 0 | 0 | 0 | 0 | 6.84M | 2.08M | 59.53M | 0 | 5.49M | 5.54M |
Deferred Revenue (Current) | 10.24M | 11.46M | 11.8M | 16.39M | 15.48M | 14.44M | 16.73M | 18.59M | 38.95M | 137.34M |
Other Current Liabilities | 10.54M | 7.62M | 3.84M | 11.21M | 8.67M | 3.96M | 12.05M | 14.71M | 58.46M | 18.68M |
Current Ratio | 2.83x | 3.38x | 2.93x | 2.17x | 1.45x | 4.81x | 1.45x | 5.70x | 4.19x | 12.36x |
Quick Ratio | 2.38x | 3.04x | 2.50x | 1.81x | 1.03x | 4.31x | 1.26x | 5.09x | 4.01x | 11.92x |
Cash Conversion Cycle | 133.36 | 117.65 | 119.27 | 136.88 | 112.17 | 145.66 | 141.26 | 185.51 | 181.77 | 256.61 |
Total Non-Current Liabilities | 222.94M | 193.95M | 78.38M | 131.46M | 131.05M | 428.33M | 361.79M | 74.73M | 35.15M | 35.79M |
Long-Term Debt | 195.24M | 172.06M | 53.82M | 54.22M | 64.21M | 62.81M | 3.98M | 299K | 299K | 23.95M |
Capital Lease Obligations | 0 | 0 | 4.32M | 38.18M | 37.55M | 34.08M | 30.37M | 26.47M | 25.04M | 70.24M |
Deferred Tax Liabilities | 16.92M | 13.71M | 11.49M | 8.7M | 4.33M | 1.05M | 841K | 1.08M | 810K | 3.85M |
Other Non-Current Liabilities | 5.83M | 1.85M | 573K | 1.33M | 882K | 312.21M | 312.32M | 6.96M | 1.21M | 11.01M |
Total Liabilities | 256.42M | 231.53M | 111.2M | 185.71M | 180.62M | 471.78M | 471.12M | 140.62M | 143.46M | 77.99M |
Total Debt | 195.24M | 172.06M | 59.98M | 95.38M | 111.65M | 102.66M | 98.21M | 33M | 30.83M | 29.49M |
Net Debt | 137.18M | 76.66M | 38.32M | 26.86M | 83.2M | 21.35M | 46.51M | -133.73M | -87.39M | -236.28M |
Debt / Equity | 6.31x | 2.39x | 0.39x | 0.69x | 1.18x | - | - | 0.07x | 0.07x | 0.05x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.45x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 3.58x |
Interest Coverage | -9.95x | -3.42x | -14.59x | -14.15x | -15.65x | -43.55x | -15.25x | -40.71x | -3718.31x | -2937.25x |
Total Equity | 30.93M▲ 0% | 72.12M▲ 133.1% | 153.61M▲ 113.0% | 139.05M▼ 9.5% | 94.6M▼ 32.0% | -81.47M▼ 186.1% | -148.05M▼ 81.7% | 471.72M▲ 418.6% | 424.29M▼ 10.1% | 561.12M▲ 0% |
Equity Growth % | -41.89% | 133.12% | 113.01% | -9.48% | -31.97% | -186.12% | -81.73% | 418.62% | -10.05% | -21.75% |
Book Value per Share | 0.94 | 1.82 | 2.30 | 1.93 | 1.25 | -1.04 | -1.87 | 1.34 | 1.11 | 1.45 |
Total Shareholders' Equity | 30.93M | 72.12M | 153.61M | 139.05M | 94.6M | -81.47M | -148.05M | 471.72M | 424.29M | 561.12M |
Common Stock | 39K | 49K | 70K | 75K | 77K | 80K | 83K | 396K | 404K | 408K |
Retained Earnings | -500.2M | -558.85M | -623.64M | -676.76M | -736M | -926.1M | -1B | -1.19B | -1.26B | -1.13B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | -563K | -5.98M | -46.47M | -46.47M | 0 |
Accumulated OCI | -574K | -687K | -582K | 112K | -907K | -1.9M | -2.22M | 1.23M | -1.49M | -511K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LAB Cash Flow Statement
Standard BioTools Inc. (LAB) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -24.1M | -25.2M | -35.21M | -15.42M | -44.06M | -89.37M | -43.29M | -143.45M | -74.35M | -90.66M |
Operating CF Margin % | -23.64% | -22.31% | -30.03% | -11.16% | -33.74% | -91.24% | -40.71% | -82.24% | -87.13% | - |
Operating CF Growth % | 38.37% | -4.58% | -39.72% | 56.21% | -185.79% | -102.83% | 51.56% | -231.4% | 48.17% | 105.02% |
Net Income | -60.53M | -59.01M | -64.79M | -53.02M | -59.24M | -190.1M | -74.66M | -138.88M | -74.9M | 78.2M |
Depreciation & Amortization | 18.61M | 16.57M | 17.74M | 15.92M | 16.2M | 15.03M | 15.18M | 16.86M | 1.72M | 10.99M |
Stock-Based Compensation | 9.09M | 11.02M | 11.39M | 14.45M | 16.1M | 14.88M | 13.12M | 31.73M | 29.61M | 27.48M |
Deferred Taxes | 0 | 141K | 0 | 212K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -468K | 8.55M | 16.96M | 4.6M | 886K | 83.17M | 1.28M | -41.08M | 14.2M | -175.2M |
Working Capital Changes | 9.2M | -2.48M | -16.51M | 2.41M | -18.01M | -12.35M | 1.79M | -12.08M | -44.98M | -32.13M |
Change in Receivables | -554K | -1.79M | -2.08M | -7.63M | 6.73M | 1.06M | -2.99M | 8.97M | -1.36M | 2.96M |
Change in Inventory | 4.6M | 1.49M | -3.05M | -8.64M | -4.78M | -8.47M | -4.91M | -9.88M | -11.52M | 841K |
Change in Payables | 585K | -294K | 0 | 3.36M | 0 | 0 | 1.62M | 0 | 2.44M | 653K |
Cash from Investing | 17.66M | 4.72M | -39.3M | 39.98M | -11.95M | -88.13M | 20.24M | 363.17M | 24.77M | 201.23M |
Capital Expenditures | -1.62M | -372K | -2.53M | -12.72M | -13.26M | -3.83M | -2.83M | -8.36M | -8.3M | -3.82M |
CapEx % of Revenue | 1.59% | 0.33% | 2.16% | 9.21% | 10.16% | 3.91% | 2.66% | 4.79% | 9.73% | 5.81% |
Acquisitions | 50K | 0 | 0 | -5.15M | 0 | 0 | 0 | 278.65M | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -50K | 5.09M | -36.77M | 21.04M | 1.32M | -84.3M | 0 | 92.88M | -5M | 381.82M |
Cash from Financing | 29M | 57.66M | 2.79M | 20.86M | 15.96M | 230.76M | -6.81M | -102.62M | 570K | 576K |
Debt Issued (Net) | 0 | 0 | 3.17M | 0 | 9.5M | 18.16M | -2.08M | -63.19M | 0 | 0 |
Equity Issued (Net) | 28.79M | 59.47M | -629K | 20.23M | -1.79M | -774K | -5.55M | -40.95M | 1.05M | 434K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | -629K | 0 | -1.79M | -774K | -5.41M | -40.95M | 0 | -312K |
Other Financing | 204K | -1.81M | 245K | 631K | 8.25M | 213.37M | 827K | 1.52M | -484K | 142K |
Net Change in Cash | 23.01M▲ 0% | 37.34M▲ 62.3% | -71.67M▼ 291.9% | 45.8M▲ 163.9% | -40.07M▼ 187.5% | 52.86M▲ 231.9% | -29.82M▼ 156.4% | 116.32M▲ 490.0% | -48.17M▼ 141.4% | 111.74M▲ 0% |
Free Cash Flow | -25.71M▲ 0% | -25.57M▲ 0.5% | -37.74M▼ 47.6% | -28.13M▲ 25.5% | -57.33M▼ 103.8% | -93.19M▼ 62.6% | -46.12M▲ 50.5% | -151.81M▼ 229.2% | -82.65M▲ 45.6% | -94.48M▲ 0% |
FCF Margin % | -25.23% | -22.64% | -32.19% | -20.37% | -43.9% | -95.15% | -43.37% | -87.03% | -96.86% | -143.85% |
FCF Growth % | 41.77% | 0.55% | -47.58% | 25.46% | -103.76% | -62.57% | 50.51% | -229.18% | 45.55% | 23.74% |
FCF per Share | -0.78 | -0.64 | -0.57 | -0.39 | -0.76 | -1.19 | -0.58 | -0.43 | -0.22 | -0.24 |
FCF Conversion (FCF/Net Income) | 0.40x | 0.43x | 0.54x | 0.29x | 0.74x | 0.47x | 0.58x | 1.03x | 0.99x | -1.21x |
Interest Paid | 5.53M | 5.53M | 3.54M | 3.09M | 3.15M | 3.49M | 3.82M | 3.09M | 0 | 11K |
Taxes Paid | 245K | 321K | 0 | 521K | 0 | 0 | 801K | 0 | 0 | 0 |
LAB Key Ratios
Standard BioTools Inc. (LAB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -143.84% | -114.53% | -57.41% | -36.23% | -50.71% | -2895.85% | - | -85.82% | -16.72% | 17.29% |
Return on Invested Capital (ROIC) | -22.96% | -22.8% | -22.82% | -21.39% | -29.44% | -148.13% | - | -111.17% | -20.74% | -17.42% |
Gross Margin | 50.99% | 54.57% | 54.83% | 60.32% | 53.13% | 37.83% | 47.44% | 48.31% | 49.86% | 51.93% |
Net Margin | -59.38% | -52.24% | -55.26% | -38.38% | -45.36% | -194.08% | -70.2% | -79.62% | -87.77% | 119.07% |
Debt / Equity | 6.31x | 2.39x | 0.39x | 0.69x | 1.18x | - | - | 0.07x | 0.07x | 0.05x |
Interest Coverage | -9.95x | -3.42x | -14.59x | -14.15x | -15.65x | -43.55x | -15.25x | -40.71x | -3718.31x | -2937.25x |
FCF Conversion | 0.40x | 0.43x | 0.54x | 0.29x | 0.74x | 0.47x | 0.58x | 1.03x | 0.99x | -1.21x |
Revenue Growth | -2.4% | 10.82% | 3.79% | 17.83% | -5.47% | -24.99% | 8.57% | 64.03% | -51.08% | -57.62% |
Related:LAB Dividend History·LAB Revenue History·LAB Price History·LAB P/E History·LAB Financial Ratios·LAB Institutional Holders
LAB SEC Filings & Documents
Standard BioTools Inc. (LAB) SEC filings — annual & quarterly reports (10-K, 10-Q)
LAB Frequently Asked Questions
Standard BioTools Inc. (LAB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Standard BioTools Inc. (LAB) reported $65.7M in revenue for fiscal year 2025. This represents a 927% increase from $6.4M in 2006.
Standard BioTools Inc. (LAB) saw revenue decline by 51.1% over the past year.
Yes, Standard BioTools Inc. (LAB) is profitable, generating $78.2M in net income for fiscal year 2025 (-87.8% net margin).
Dividend & Returns
Standard BioTools Inc. (LAB) has a return on equity (ROE) of -16.7%. Negative ROE indicates the company is unprofitable.
Standard BioTools Inc. (LAB) had negative free cash flow of $94.5M in fiscal year 2025, likely due to heavy capital investments.